Osiris Announces Receipt of $15 Million Milestone Payment for Prochymal

Osiris Therapeutics, Inc. , the leading stem cell company focused on developing and marketing products to treat conditions in orthopedic, sports medicine and wound care markets announced that it has received a $15 million milestone payment from Mesoblast for successful completion of the transfer of assets relating to the Prochymal business.

http://www.businesswire.com/news/topix/20131220005432/en